Worldwide Sales Of Nuclear Medicine Radioisotopes Are Predicted To Increase At A CAGR Of 8% Through 2033: Fact.MR

Published April 22, 2023

As per a new industry analysis by Fact.MR, a market research and competitive intelligence provider, the global nuclear medicine radioisotopes market is valued at US$ 8.82 billion in 2023 and is predicted to reach US$ 19.04 billion by the end of 2033.

Medical radioisotopes are harmless radioactive compounds that are typically employed in the diagnosis of medical disorders. These radioisotopes release gamma rays that are powerful enough to escape the body when they are used to diagnose a disease.

Dales of nuclear medicine radioisotopes are expected to rise rapidly during the forecast period due to the increasing rate of cancer cases and growing public knowledge of nuclear therapies. A radiopharmaceutical is a pharmaceutical formulation containing radioactive isotopes used in diagnosis and treatment. They are small, straightforward radioactive compounds used to treat cancer, heart and neurological diseases.

Download a Free Sample Copy of this Report –

Report Attributes Details
Nuclear Medicine Radioisotopes Market Size (2023E) US$ 8.82 Billion
Forecasted Market Value (2033F) US$ 19.04 Billion
Global Market Growth Rate (2023 to 2033) 8% CAGR
No. of Pages 170 pages
No. of Tables 52 Tables
No. of Figures 56 Figures

For oncology and treatment for cancer, therapeutic radioisotopes are replacing traditional chemotherapy procedures because they are more practical, which is further generating new opportunities in the nuclear medicine radioisotopes market. Furthermore, when compared to X-Rays and other external radiation imaging systems, radioisotopes serve as an accurate & safe alternative for patients as well as aiding doctors during diagnosis.

The technetium-99 radioisotope is expected to account for a sizable share of the global market in 2023 due to its expanding use in diagnostics.

  • The World Nuclear Organization estimates that around 40 million treatments a year, or almost 80% of all nuclear procedures performed worldwide, are performed with technetium-99.

Key Takeaways from Market Study

  • The global nuclear medicine radioisotopes market is expected to increase at a CAGR of 8% from 2023 to 2033.
  • Germany’s market for nuclear medicine radioisotopes is predicted to expand at a CAGR of 6.5% during the projected period.
  • Global sales of technetium-99m (Tc-99m) radioisotopes are expected to rise at a CAGR of 9% during the forecast period.
  • Demand for thallium-201 (Tl-201) radioisotopes is predicted to expand at a CAGR of 6.5% during the next 10 years.

Get Customization on this Report for Specific Research Solutions –

Recent Market Developments

  • Technetium-99m (Tc-99m), the most popular medical radioisotope, will be more readily available worldwide starting in March 2021 due to a collaboration between IBA (Ion Beam Applications SA) and NorthStar Medical Radioisotopes LLC.
  • To commercialize and develop advanced alpha-emitting radiopharmaceutical and combination therapies for cancer therapy, Fusion Pharmaceuticals, a leading Canadian radiopharmaceutical company, announced collaboration with Anglo-Swedish pharmaceutical behemoth AstraZeneca in November 2020.

Key Companies Profiled

  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • GE Healthcare
  • Hologic, Inc.
  • Lantheus Medical Imaging, Inc.
  • Medtronic PLC
  • NTP Radioisotopes SOC Ltd.
  • Positron Corporation
  • Siemens Healthineers

Explore Our Safe & Secure Payment Options for Quick Buy –

Segments of Nuclear Medicine Radioisotopes Industry Research

  • By Radioisotope Type :
    • Technetium-99m (Tc-99m)
    • Thallium-201 (Tl-201)
    • Gallium-67 (Ga-67)
    • Iodine (I-123)
  • By Application :
    • Cardiology
    • Oncology
    • Neurology
    • Lymphoma
    • Thyroid
  • By End User :
    • Hospitals
    • Diagnostic Centers
    • Specialty Clinics
    • Education & Research Institutes
  • By Region :
    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

This Press Release has been written with the intention of providing accurate market information which will enable our readers to make informed strategic investment decisions. If you notice any problem with this content, please feel free to reach us on


Xherald is passionate about offering extensive coverage of global business news. Dedicated to creating every participant's notification, it reaches its own reader. Daily our experts offer fresh relevant information regarding what is actually occurring in Markets as well as Business. Our headlines are actually swiftly paced and extensive. Our distributor directory connects you with brand new products or services and its market situation from the most effective companies around the planet. Xherald is driven by its 500+ contributors coming from around the world. Xherald provides local as well as global market intelligence information coverage in sectors ranging from healthcare, IOT, chemicals and 17 more sectors. Our updates are quickly paced and detailed. The news we present is actually a mix of authentic content, community contributions and curated headlines announcements. All of the updates our company supplies must pass a strict criterion of genuineness, relevance and significance to our readers.